Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock BOLD vs. ADCT, ACRV, ACRS, AMRN, FULC, NKTR, PBYI, CYBN, TLSA, and LRMRShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include ADC Therapeutics (ADCT), Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), Amarin (AMRN), Fulcrum Therapeutics (FULC), Nektar Therapeutics (NKTR), Puma Biotechnology (PBYI), Cybin (CYBN), Tiziana Life Sciences (TLSA), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. ADC Therapeutics Acrivon Therapeutics Aclaris Therapeutics Amarin Fulcrum Therapeutics Nektar Therapeutics Puma Biotechnology Cybin Tiziana Life Sciences Larimar Therapeutics Audentes Therapeutics (NASDAQ:BOLD) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has preferable earnings and valuation, BOLD or ADCT? Audentes Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAudentes TherapeuticsN/AN/A-$49.43MN/AN/AADC Therapeutics$70.72M2.03-$240.05M-$2.39-0.62 Do analysts rate BOLD or ADCT? Audentes Therapeutics presently has a consensus target price of $23.00, indicating a potential upside of 1,436.41%. ADC Therapeutics has a consensus target price of $8.50, indicating a potential upside of 472.39%. Given Audentes Therapeutics' higher possible upside, analysts plainly believe Audentes Therapeutics is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Audentes Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor BOLD or ADCT? Audentes Therapeutics received 410 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 69.12% of users gave Audentes Therapeutics an outperform vote while only 68.18% of users gave ADC Therapeutics an outperform vote. CompanyUnderperformOutperformAudentes TherapeuticsOutperform Votes47069.12% Underperform Votes21030.88% ADC TherapeuticsOutperform Votes6068.18% Underperform Votes2831.82% Do insiders & institutionals have more ownership in BOLD or ADCT? 41.1% of ADC Therapeutics shares are owned by institutional investors. 5.3% of Audentes Therapeutics shares are owned by company insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is BOLD or ADCT more profitable? Audentes Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Audentes TherapeuticsN/A -321.10% -40.02% ADC Therapeutics -300.00%N/A -61.33% Does the media refer more to BOLD or ADCT? In the previous week, ADC Therapeutics had 6 more articles in the media than Audentes Therapeutics. MarketBeat recorded 10 mentions for ADC Therapeutics and 4 mentions for Audentes Therapeutics. ADC Therapeutics' average media sentiment score of 0.29 beat Audentes Therapeutics' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Audentes Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAudentes Therapeutics and ADC Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.60M$6.90B$5.64B$7.84BDividend YieldN/A2.74%4.59%4.01%P/E RatioN/A7.2023.4718.71Price / SalesN/A218.61388.1890.76Price / CashN/A65.6738.1734.64Price / BookN/A6.386.894.23Net Income-$49.43M$142.34M$3.20B$247.47M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics1.2526 of 5 stars$1.50-34.9%$23.00+1,436.4%N/A$44.60MN/A0.00207Earnings ReportShort Interest ↑News CoverageGap UpADCTADC Therapeutics2.1452 of 5 stars$1.79-3.5%$8.50+376.2%-66.9%$172.59M$70.72M-0.75310Earnings ReportShort Interest ↓News CoverageGap UpACRVAcrivon Therapeutics2.2952 of 5 stars$5.50+1.1%$23.67+330.3%-68.7%$171.25MN/A-2.0458Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageACRSAclaris Therapeutics2.1342 of 5 stars$1.58+1.3%$11.67+638.4%+28.2%$170.51M$18.72M-3.04100Short Interest ↑AMRNAmarin0.9453 of 5 stars$0.42+0.3%N/A-50.6%$170.43M$228.61M-4.61360Short Interest ↓FULCFulcrum Therapeutics1.713 of 5 stars$3.12flat$8.63+176.4%-68.1%$168.41M$80M-10.06100News CoveragePositive NewsNKTRNektar Therapeutics4.1677 of 5 stars$0.91+1.4%$4.92+440.7%-20.8%$167.73M$93.14M-1.08220Options VolumePBYIPuma Biotechnology4.3241 of 5 stars$3.24-2.4%$7.00+116.0%-40.8%$164.71M$230.47M6.75200CYBNCybin2.3684 of 5 stars$7.65+1.1%$86.00+1,024.2%+1,525.2%$164.30MN/A-1.7550TLSATiziana Life Sciences0.611 of 5 stars$1.55-1.3%N/A+146.7%$163.36MN/A0.008Short Interest ↑LRMRLarimar Therapeutics1.9404 of 5 stars$2.55-1.5%$20.13+689.2%-69.0%$162.71MN/A-2.2230Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies ADC Therapeutics Competitors Acrivon Therapeutics Competitors Aclaris Therapeutics Competitors Amarin Competitors Fulcrum Therapeutics Competitors Nektar Therapeutics Competitors Puma Biotechnology Competitors Cybin Competitors Tiziana Life Sciences Competitors Larimar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLD) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
